As a leader in the infectious disease field, Spero Therapeutics is highly committed to advancing new therapies for patients with rare orphan diseases and serious, multi-drug resistant bacterial infections in both hospital and community settings.
Oral antibiotic designed to treat Nontuberculous Mycobacterial Pulmonary disease, a rare disease
SPR720 has potential to be the first approved novel oral agent for nontuberculous mycobacterial (NTM), addressing a significant unmet need to arrest infection and prevent the lung damage that infection causes. If approved, the broad spectrum oral candidate may be applicable to both non-refractory and refractory patients. Once daily dosing is supported by clinical and non-clinical studies.
Nontuberculous Mycobacterium (NTM) pulmonary disease is a growing global health concern and a significant unmet medical need, due to a lack of new medications being developed to combat these bacteria. Treatment failure is common for patients with NTM. The absence of effective and well-tolerated drugs leaves patients without options and increasingly desperate for solutions.
Spero is answering the call with an audacious mission to find new answers and new treatment approaches to combat rare diseases and MDR bacterial infections for future generations.
Spero Therapeutics is pursuing collaborations with partners for expertise and funding support.
Collaborative. Exciting. Challenging. Stimulating. Committed. Find opportunities to join our team.
Stock information, SEC filings, corporate governance, IR resources and more.